HPS0754-95
170809-51-5
默认>95%HPLC，若需其他规格请洽询
| 产品编号 | 规格 | 货期 | 销售价 | 折扣价 | 数量 | 操作 |
|---|---|---|---|---|---|---|
| HPS0754-95 | 默认>95%HPLC，若需其他规格请洽询 |
25天
|
敬请询价 | 敬请询价 |
 
|
| 名字 | Astressin trifluoroacetate salt |
|---|---|
| 序列(三字母) | H-D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-cyclo(-Glu-Ala-His-Lys)-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH₂ trifluoroacetate salt |
| 序列(单字母) | fHLLREVLE-NleRAAEQLAQ-cyclo(-EAHK)-NRKL-Nle-EII-NH₂ trifluoroacetate salt |
| CAS# | 170809-51-5 |
| 分子式 | C₁₆₁H₂₆₉N₄₉O₄₂ |
| 分子量 | 3563.24 |
| 纯度 | 默认>95%HPLC，若需其他规格请洽询 |
| 合成方法 | Synthetic |
| 储存条件 | -20 ± 5 °C |
| 应用 | Pituitary & Hypothalamic Hormones |
| 描述 | The Glu³⁰ to Lys³³ lactam bridge constrains astressin in an α-helical conformation which seems to be responsible for its especially high CRF antagonist activity. Astressin is 100 times more potent than α-helical CRF (9-41) at inhibiting ACTH secretion in vitro, and more than 10 times more potent in vivo than any other CRF antagonist reported to date. |
